Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial.
|Articles|April 27, 2019
The ID Pipeline: FDA Activity From the Week of April 21, 2019
Author(s)Contagion® Editorial Staff
Here is a look at infectious disease-related US Food and Drug Administration news from the week of April 21, 2019.
Advertisement
Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of April 21, 2019.
FDA Grants Breakthrough Therapy Designation for Investigational Drug to Treat Severe Malaria
On Wednesday, April 24, the FDA granted Breakthrough Therapy designation to La Jolla Pharmaceutical Comapny for the New Investigational Drug Product LJPC-0118 for the treatment of severe malaria.
In 2 randomized, controlled, clinical studies, the active ingredient in LJPC-0118 proved superior to quinine in reducing mortality in patients with severe falciparum malaria infection.
“We are committed to the rapid development of LJPC-0118 to help patients suffering from severe malaria, a serious and life-threatening disease without a current FDA-approved therapy. We are very pleased to receive the Breakthrough Therapy designation from the FDA and are committed to providing LJPC-0118 to patients in the US,” George Tidmarsh, MD, PhD, La Jolla’s president and CEO, said in a company statement. “This designation is a key regulatory milestone and we look forward to working closely with the FDA to further develop LJPC-0118.”
La Jolla plans to file a New Drug Application with the FDA for LJPC-0118 in the fourth quarter of 2019.
The full press release is available
Advertisement
Related to this article
CDC is continuing its investigation into 4 multistate Salmonella and E coli outbreaks, led by a 76-case alfalfa sprout cluster across 16 states and a recalled raw milk cheese.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Demonstrating a diagnostic test works is no longer enough. Clinicians and laboratories also need evidence on how to adopt it in everyday practice. Andrea Prinzi, PhD, MPH, SM(ASCP), explains how implementation science can help infectious disease and clinical microbiology teams turn evidence into routine care.
Kenya reported its first imported Bundibugyo Ebola death as the Democratic Republic of Congo (DRC) outbreak surpassed 8,600 confirmed cases and 4,148 deaths, with 896 patients hospitalized in isolation. Here is a report on the latest numbers as well as vaccine and therapeutic study updates.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Advertisement
Advertisement